flosz schreef:
Elias Zerhouni weer gevonden.
****************
Sanofi said it was targeting acquisitions and partnerships, aiming to reinforce its regional approach and its external research collaborations to boost innovation and creativity in research and development.
It said it named Chief Financial Officer Laurence Debroux to the new post of Chief Operating Officer. Debroux will remain finance director, pending the imminent appointment of a successor.
To prop up its R&D, Sanofi said it had begun reviewing its portfolio of drugs and that it had created the posts of Chief Medical Officer, to be taken up by Jean-Pierre Lehner, and Scientific Advisor, which will be taken up by Elias Zerhouni.
uk.reuters.com/article/americasMerger..._____________________
Uit 2008: Bethesda, MD (Sept. 24)—Elias A. Zerhouni, MD, the director of the National Institutes of Health (NIH), plans to step down at the end of October 2008 to pursue writing projects and explore other professional opportunities. Zerhouni served as NIH director since May 2002.
_________________________
Viehbacher's appointment has buoyed expectations Sanofi will embark on a string of small to medium-sized takeovers, boost cost cuts and restructure its research and development to make up for new drug setbacks and looming loss of patents.
Pfizer (nyse: PFE - news - people )'s planned $68 billion purchase of Wyeth, announced last month, has sparked speculation of a new wave of consolidation in the fragmented pharmaceutical industry.
Viehbacher has already made clear he plans to use the 4 billion euros that Sanofi generates annually in free cash flow to help it grow through acquisitions.
But making a play for its U.S. partner Bristol-Myers Squibb (nyse: BMY - news - people ) , which has a market value of around $45 billion, might be a step too far for Viehbacher so soon after becoming CEO. There has been persistent speculation that Sanofi could buy BMS.
Instead, buying promising small to medium-sized companies -- such as Dutch vaccine maker Crucell which has a market capitalisation of some 1 billion euros -- may be more manageable, according to analysts.
www.forbes.com/feeds/reuters/2009/02/...